Tucatinib is an oral reversible TKI highly selective only for HER2, and it is being investigated in association with trastuzumab in a phase II study for all solid tumours that includes HER2-alterated (AMP and MUT) NSCLC (SGNTUC-019 trial) [77]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.